MP
Therapeutic Areas
Novocure Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Optune® (TTFields + Temozolomide) | Newly Diagnosed Glioblastoma (GBM) | Approved |
| Optune® (TTFields) | Recurrent Glioblastoma (GBM) | Approved |
| Optune Pax® (TTFields) | Locally Advanced Pancreatic Cancer (LAPC) | Approved |
| TTFields | Non-Small Cell Lung Cancer (NSCLC) | Phase 3 |
Leadership Team at Novocure
FL
Frank Leonard
Chief Executive Officer
WF
William F. Doyle
Executive Chairman
CB
Christoph Brackmann
Chief Financial Officer
MP
Mukund Paravasthu
Chief Operating Officer
UW
Uri Weinberg, M.D., Ph.D.
Chief Innovation Officer
BB
Barak Ben-Arye
General Counsel
AD
Asaf Danziger
Board of Directors
KG
Kinyip Gabriel Leung
Board of Directors
JH
Jeryl Hilleman
Board of Directors
DT
David T. Hung
Board of Directors